December 29, 2014 11:16 AM ET

Pharmaceuticals

Company Overview of Kalypsys, Inc.

Executive Profile

Paul C. Grint M.D.

Chief Medical Officer, Regulus Therapeutics Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 9 different industries.

See Board Relationships
56--

Background

Dr. Paul C. Grint, MD has been Chief Medical Officer of Regulus Therapeutics Inc. since June 16, 2014. Dr. Grint joined Regulus from Cerexa, Inc., a wholly-owned subsidiary of Forest Laboratories, Inc., where he served as President and was responsible for the oversight of anti-infective product development. Prior to joining Cerexa, Dr. Grint was a Senior Vice President at Forest Research Institute, Inc., a subsidiary of Forest Laboratories, Inc. He served as the Chief ...

Corporate Headquarters

10420 Wateridge Circle
San Diego, California 92121

United States

Phone: 858-754-3460
Fax: 858-754-3301

Board Members Memberships

2005-2013
Former Director and Member of Compensation Committee
2008-Present
Director

Education

Bachelor's Degree
Barts & The London School of Medicine & Dentistry, Queen Mary University of London
MD
Saint Bartholomew Medical School, London University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
$70.0K
Peter French B.Sc, M.Sc, Ph.D., MBAChief Executive Officer, Managing Director and Director
Benitec Biopharma Limited
$450.0K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kalypsys, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.